Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment.

Abstract : Remissions of haematological malignancies have been reported after allo-SCT, despite donor cell rejection, suggesting that sustained allogeneic engraftment is not mandatory to obtain a lasting anti-tumour effect. To evaluate the potential benefit from transient post-allo-SCT alloreactivity, we took advantage of the Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC) registry to colligate 14 patients with an efficient and long-lasting allogeneic (GVL) effect after allo-SCT for haematological malignancies, despite transient or absent engraftment. None received a second allogeneic graft after autologous recovery. The median duration of remission after autologous reconstitution was 118 (12-252) months. Although we cannot exclude the possibility that some patients were cured before allo-SCT, this retrospective analysis does strongly suggest that an efficient GVL effect can be observed without sustained donor engraftment, and that the transient presence of donor T cells might be sufficient to induce a powerful GVL effect.
Type de document :
Article dans une revue
Bone Marrow Transplantation, Nature Publishing Group, 2010, 45 (1), pp.177-80. 〈10.1038/bmt.2009.96〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00484316
Contributeur : Philippe Saas <>
Soumis le : mardi 18 mai 2010 - 12:03:45
Dernière modification le : mercredi 29 août 2018 - 01:10:29

Lien texte intégral

Identifiants

Citation

E. Daguindau, B. Lioure, A. Buzyn, M. Robin, C. Faucher, et al.. Evidence for anti-tumour effect of allogeneic haematopoietic SCT in cases without sustained donor engraftment.. Bone Marrow Transplantation, Nature Publishing Group, 2010, 45 (1), pp.177-80. 〈10.1038/bmt.2009.96〉. 〈inserm-00484316〉

Partager

Métriques

Consultations de la notice

112